GGrantIndex
Sort

82,697 grants matching vaccine development

Development of Technologies to Facilitate the Use of and Response to Vaccines

$2,045,144
Laurence Lemiale · Emergent Product Development Gaithersbur · N01 · FY2013 · AI

SPORE for Translational Approaches to Brain Cancer

$2,044,971
Maciej S Lesniak · Northwestern University At Chicago · P50 · FY2023 · CA

NIAID Preclinical Development Support

$2,044,894
Advanced Bioscience Laboratories, Inc. · N01 · FY2012 · AI

Vaccine and Treatment Evaluation Units

$2,044,564
Nadine Georges Rouphael · Emory University · UM1 · FY2021 · AI

Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses

$2,044,217
Fred R Hirsch · Icahn School Of Medicine At Mount Sinai · U54 · FY2022 · CA

Impact of Immunotherapy on Viral Immunity in Humans

$2,043,956
Raymond T Chung · Massachusetts General Hospital · U19 · FY2023 · AI

Impact of Immunotherapy on Viral Immunity in Humans

$2,043,956
Raymond T Chung · Massachusetts General Hospital · U19 · FY2019 · AI

Impact of Immunotherapy on Viral Immunity in Humans

$2,043,956
Raymond T Chung · Massachusetts General Hospital · U19 · FY2021 · AI

Impact of Immunotherapy on Viral Immunity in Humans

$2,043,956
Raymond T Chung · Massachusetts General Hospital · U19 · FY2022 · AI

Impact of Immunotherapy on Viral Immunity in Humans

$2,043,956
Raymond T Chung · Massachusetts General Hospital · U19 · FY2020 · AI

Enhancing racial and ethnic diversity inCOVID-19 research participation through storytelling (COVIDstory)

$2,043,738
Ann M Moormann · Univ Of Massachusetts Med Sch Worcester · U01 · FY2020 · CA

Papillomavirus Virion Proteins and Vaccines

$2,043,490
John T. Schiller · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Influenza Vaccine Development

$2,042,985
Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

Emerging respiratory viruses - pathogenesis and countermeasures

$2,042,870
Emmie De Wit · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI

CORE C: Structure & Protein Engineering Core

$2,042,293
Jason Scott McLellan · Albert Einstein College Of Medicine · U19 · FY2025 · AI

Improving the safety profile of DNA prime - protein boost HIV vaccinations

$2,042,130
Egil Lien · Univ Of Massachusetts Med Sch Worcester · U19 · FY2011 · AI

EVALUATION OF THE IMMUNOGENICITY AND EFFICACY OF HIV-1 CLADE C OLIGOMERIC ENVELOPE PROTEIN DELIVERED WITH ADVAX DELTA INULIN ADJUVANT BY INTRAMUSCULAR AND INTRAPULMONARY ROUTES

$2,041,729
Ranajit Pal · Advanced Bioscience Laboratories, Inc. · N01 · FY2018 · AI

CENTER FOR RECOMBINANT GAMETE CONTRACEPTIVE VACCINOGENS

$2,041,686
University Of Virginia Charlottesville · U54 · FY2000 · HD

Thymic vaccination: Manipulating the T cell repertoire

$2,041,678
Dana-Farber Cancer Institute · R01 · FY2001 · AI

Preclinical GEM and GDA Models of Primary and Metastatic Melanoma

$2,041,466
Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

CHARACTERIZING AND IMPROVING HUMANIZED IMMUNE SYSTEM MOUSE MODELS (IMM-HIS)

$2,041,443
Julie Lang · University Of Colorado Denver · N01 · FY2020 · AI

Correlates of protective immunity to HCV and rational vaccine design

$2,040,307
Arash Grakoui · Emory University · U19 · FY2022 · AI

HIV LCMV vaccines

$2,040,198
Richard Schwartz · National Institute Of Allergy And Infectious Diseases · ZIB · FY2010 · AI

Immunobiology, molecular virology and countermeasures of highly pathogenic viruses

$2,039,904
Andrea Marzi · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI

Recombinant Subunit Vaccine/Prevention of West Nile Vir*

$2,039,391
Hawaii Biotech, Inc. · R44 · FY2005 · NS